Keywords: fda, approves, ligand, ontak, cutaneous, cell, lymphoma

FDA approves Ligand's Ontak for cutaneous T cell lymphoma

Article | 11 February 1999

Print This

Ligand has been granted fast-track approval by the US Food and DrugAdministration to market Ontak (denileukin diftitox; DAB389IL-2) for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in